Stockscreener 앱 받기
10.41
3.79%
0.38
시간 외 거래:
10.41
전일 마감가:
$10.03
열려 있는:
$10.09
하루 거래량:
241.77K
Relative Volume:
0.65
시가총액:
$206.03M
수익:
$244.06M
순이익/손실:
$87.01M
주가수익비율:
5.7157
EPS:
1.8213
순현금흐름:
$105.95M
1주 성능:
+4.83%
1개월 성능:
-0.86%
6개월 성능:
-50.02%
1년 성능:
-22.66%
1일 변동 폭
$10.09
$10.52
1주일 범위
$9.69
$10.52
52주 변동 폭
$9.69
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
10.41 | 202.67M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics director Charles W. Newton sells $5,521 in shares - Investing.com
Insider Sell: Charles Newton Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics Hits 52-Week Low at $9.69 Amidst Major Decline - Markets Mojo
Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside - TradingView
KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline AdvancesNon-GAAP Earnings - newsline.com
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Keros Therapeutics director Nima sells $28,166 in company stock By Investing.com - Investing.com Nigeria
KROS: KER-065 targets muscle regeneration in DMD, with strong early data and a solid financial runway - TradingView
Keros Therapeutics director Nima sells $28,166 in company stock - Investing.com
Director at Keros Therapeutics (NASDAQ: KROS) logs 2,625-share sale - Stock Titan
Director at Keros Therapeutics (KROS) sells 2,625 shares in Rule 10b5-1 trade - Stock Titan
Keros Therapeutics (KROS) Faces Selling Pressure as Shares Approach Key SupportATR Trailing Stop - newsline.com
How (KROS) Movements Inform Risk Allocation Models - Stock Traders Daily
Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics director granted RSUs and options | KROS Insider Trading - Stock Titan
Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards - Stock Titan
Keros Therapeutics (KROS) grants RSUs and stock options to director - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant - Stock Titan
Keros Therapeutics (KROS) director awarded RSUs and stock options - Stock Titan
Keros Therapeutics Stockholders Approve Directors and Governance Matters - TipRanks
Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% Upside - TradingView
Keros Therapeutics CEO to Present at Goldman Sachs Conference - The Globe and Mail
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Keros Therapeutics CEO to speak at Goldman Sachs health conference - Stock Titan
Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat - Stock Titan
KROS Q1 2026 Earnings: EPS Miss of $1.21 as Pre-Revenue Biotech Continues Clinical InvestmentTech Earnings Analysis - newsline.com
Keros Therapeutics (KROS) Edges Lower Near Key Support ZoneDescending Triangle - The Legal Advocate
Keros Therapeutics (KROS) Edges Higher Amid Consolidation Near Key ResistanceResistance Breakout Stocks - The Legal Advocate
Trading Systems Reacting to (KROS) Volatility - Stock Traders Daily
Keros Therapeutics (KROS) Edges Higher as Biotech Sector Shows Mixed SignalsVolume Breakout Ideas - newsline.com
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies - The Globe and Mail
Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - The Globe and Mail
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - The Globe and Mail
Keros Therapeutics (KROS) Q1 2026 Disappoints — EPS $-1.21 Below $-1.04 ViewsQuarterly Earnings Report - Newser
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles - Streetwise Reports
Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans - Streetwise Reports
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Keros Therapeutics, Inc.common stock (NQ: KROS - The Chronicle-Journal
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $20 to $20 - Moomoo
Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):